Cellectis to Present at the 2017 Annual Conference of the American Association for Cancer Research

New York, N.Y. – March 29, 2017 – Cellectis (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), today announced that data on its gene-edited allogeneic CAR T-cells will be presented at the American Association for Cancer Research (AACR) Annual Meeting. This includes both wholly controlled Cellectis programs and Pfizer/Cellectis collaboration programs. The meeting will be held from April 1st to April 5th, 2017 in Washington, D.C., USA.

Cellectis presentation:

• UCART22: An Allogeneic Adoptive Immunotherapy for Leukemia Targeting CD22 with CAR T-cells 

Agnès Gouble¹, Cécile Schiffer-Mannioui¹, Séverine Thomas¹, Anne-Sophie Gautron¹, Laurent Poirot¹, Julianne Smith².

¹Cellectis, Paris, France; ²Cellectis, New York, NY

Innate Effectors in Immunity to Cancer session – section 30

April 4, 2017, 8:00 AM - 12:00 PM Eastern Time

Pfizer/Cellectis presentations:

• Allogeneic EGFRvIII Chimeric Antigen Receptor T Cells for Treatment of Glioblastoma

Oi Kwan Wong¹, Mathilde Dusseaux², Jing-Tyan Ma¹, Melinda Au¹, Sophie Leduc², Joyce Chou¹, Jessica M. Yu¹, Marjorie Bateman¹, Thomas Pertel¹, Kevin C. Lindquist¹, Julianne Smith³, Barbra Sasu¹, Shu-Hui Liu¹.

¹Pfizer Inc., South San Francisco, CA; ²Cellectis, Paris, France; ³Cellectis, New York, USA

Innate Effectors in Immunity to Cancer session – section 30

April 4, 2017, 8:00 AM - 12:00 PM Eastern Time

• Differential modulation of the PD-1 pathway impacts the anti-tumor activity of CAR T cells

Regina J. Lin¹, Anne-Sophie Gautron², Laurent Poirot², Oi Kwan Wong¹, Barbra Sasu¹, Bijan Boldajipour¹.

¹Pfizer, South San Francisco, CA; ²Cellectis, Paris, France; ³Cellectis, New York, USA

Late-Breaking Research: Immunology session – section 35

April 4, 2017, 8:00 AM - 12:00 PM Eastern Time

Collaboration with Pfizer

In June 2014, Cellectis and Pfizer began collaborating on a joint clinical development program for UCAR-T therapies, in the field of oncology, directed at numerous targets selected by Pfizer and several targets selected by Cellectis.